Aromatase inhibitor use, side-effects and discontinuation rates in gynecologic oncology patients

Bell, Sherry; McNeish, Brendan; Dalton, Liam; McLean, Karen

doi:10.1016/j.ygyno.2019.03.142

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among patients who switched to a different AI due to adverse effects in this study, only 38% of patients were able to tolerate a second AI for a median of 13 months. Within the gynecologic oncology literature, one retrospective study found similar rates of AIMSS symptoms in women on AI therapy at equivalent doses for primarily advanced stage ovarian or uterine cancer, though only 5.0% of patients discontinued AI therapy due adverse effects ( 38 ). The authors of this study hypothesized that the gynecologic oncology sample was more likely to continue AI therapy since their sample population had more advanced disease on average than in breast cancer adjuvant therapy studies, however data is comparatively limited in the gynecologic oncology setting.…”

Section: Prevalence and Associated Risk Factorsmentioning

confidence: 99%

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

et al. 2021

View full text Add to dashboard Cite

Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast cancer, AIs are associated with musculoskeletal adverse effects known as the aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) that limit its tolerability and use. AIMSS is mainly comprised of AI-associated bone loss and arthralgias that affect up to half of women on AI therapy and detrimentally impact patient quality of life and treatment adherence. The pathophysiology of AIMSS is not fully understood though has been proposed to be related to estrogen deprivation within the musculoskeletal and nervous systems. This review aims to characterize the prevalence, risk factors, and clinical features of AIMSS, and explore the syndrome’s underlying mechanisms and management strategies.

show abstract

Section: Prevalence and Associated Risk Factorsmentioning

confidence: 99%

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

et al. 2021

View full text Add to dashboard Cite

show abstract

Aromatase inhibition using Juniperus procera phytochemical constituents: molecular docking study

Al-Zahrani

2024

J.Umm Al-Qura Univ. Appll. Sci.

View full text Add to dashboard Cite

The key step in the biosynthesis of estrogen is the enzyme activity of aromatase. Several malignancies, including breast cancer, have been linked to the initiation and progression of estrogen overexpression. Exemestane, Arimidex and Femara are the most common aromatase inhibitors used to treat hormone-dependent breast cancers. Drug resistance and side effects are commonly associated with these treatments. The purpose of this in silico study was to list the chemical compounds of Juniperus procera that have been published in scientific papers. The second goal was to evaluate the inhibitory activity of 124 phytochemicals of Juniperus procera compared to known aromatase inhibitors such as Exemestane, Arimidex and Femara. The 3D structure of aromatase (PDB id: 3s7s) employed for docking studies using AutoDock Tools as well as normal mode analysis studies utilizing the NMSim web server. Juniperolide, Kaurenoic acid and Isocupressic acid were identified as competitive aromatase inhibitors compared to FDA approved anti-cancer drugs, specifically Exemestane, Arimidex and Femara. The stability of the ligand–protein interface was studied to support the docking findings. To our knowledge, this is the first study that investigates the possible inhibition roles of some compounds of Juniperus procera on the aromatase enzyme.

show abstract

Aromatase inhibitor use, side-effects and discontinuation rates in gynecologic oncology patients

Cited by 2 publications

References 0 publications

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

Aromatase inhibition using Juniperus procera phytochemical constituents: molecular docking study

Contact Info

Product

Resources

About